Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -784,955 | -601,924 | -295,746 | -161,376 | -589,526 |
| Depreciation Amortization | 10,125 | 7,264 | 4,585 | 2,300 | 9,531 |
| Accounts receivable | -1,114 | 14,842 | 8,240 | 14,638 | -15,367 |
| Accounts payable and accrued liabilities | 2,663 | 2,972 | -3,626 | -4,576 | -4,483 |
| Other Working Capital | -35,628 | -33,783 | -56,314 | -5,203 | 35,664 |
| Other Operating Activity | 298,900 | 243,271 | 83,008 | 22,600 | 168,291 |
| Operating Cash Flow | $-510,009 | $-367,358 | $-259,853 | $-131,617 | $-395,890 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | -5,000 | N/A |
| PPE Investments | -24,807 | -19,163 | -9,809 | -5,664 | -3,906 |
| Purchase Of Investment | -1,068,173 | -722,523 | -382,071 | -159,105 | -1,293,416 |
| Sale Of Investment | 1,109,646 | 829,544 | 550,717 | 275,725 | 744,225 |
| Investing Cash Flow | $16,666 | $87,858 | $158,837 | $105,956 | $-553,097 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 729,460 | 729,460 | N/A | N/A | N/A |
| Debt Repayment | -413,513 | -410,791 | -5,582 | -2,884 | -9,618 |
| Common Stock Issued | N/A | N/A | N/A | 7,651 | 656,844 |
| Other Financing Activity | 208,511 | 95,084 | 88,869 | -13 | 283,385 |
| Financing Cash Flow | $524,458 | $413,753 | $83,287 | $4,754 | $930,611 |
| Exchange Rate Effect | -715 | -906 | -952 | -270 | 209 |
| Beginning Cash Position | 95,232 | 95,232 | 95,232 | 95,232 | 113,399 |
| End Cash Position | 125,632 | 228,579 | 76,551 | 74,055 | 95,232 |
| Net Cash Flow | $30,400 | $133,347 | $-18,681 | $-21,177 | $-18,167 |
| Free Cash Flow | |||||
| Operating Cash Flow | -510,009 | -367,358 | -259,853 | -131,617 | -395,890 |
| Capital Expenditure | -24,807 | -19,163 | -9,809 | -5,664 | -3,906 |
| Free Cash Flow | -534,816 | -386,521 | -269,662 | -137,281 | -399,796 |